BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15231579)

  • 1. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
    Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
    Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
    Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
    Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
    Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
    Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
    Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
    Tykodi SS; Fujii N; Vigneron N; Lu SM; Mito JK; Miranda MX; Chou J; Voong LN; Thompson JA; Sandmaier BM; Cresswell P; Van den Eynde B; Riddell SR; Warren EH
    Clin Cancer Res; 2008 Aug; 14(16):5260-9. PubMed ID: 18698046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
    Bernhard H; Maeurer MJ; Jäger E; Wölfel T; Schneider J; Karbach J; Seliger B; Huber C; Storkus WS; Lotze MT; Meyer zum Büschenfelde KH; Knuth A
    Scand J Immunol; 1996 Sep; 44(3):285-92. PubMed ID: 8795723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
    Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
    Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
    Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
    Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
    Warren EH; Greenberg PD; Riddell SR
    Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma.
    Brouwenstijn N; Hoogstraten C; Verdegaal EM; Van der Spek CW; Deckers JG; Mulder A; Osanto S; Schrier PI
    J Immunother; 1998 Nov; 21(6):427-34. PubMed ID: 9807737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.
    LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS
    Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
    Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.